We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGM - Delayed Quote USD

Keen Vision Acquisition Corporation (KVACU)

11.20

+0.05

+(0.45%)

As of March 3 at 4:00:00 PM EST. Market Open.

Key Events

Loading Chart for KVACU

Previous Close 11.15
Open 11.20
Bid --
Ask --
Day's Range 11.20 - 11.20
52 Week Range 10.46 - 13.72
Volume 6
Avg. Volume 577
Market Cap (intraday) --
Beta (5Y Monthly) --
PE Ratio (TTM) --
EPS (TTM) --
Earnings Date May 13, 2025 - May 19, 2025
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.

--

Full Time Employees

December 31

Fiscal Year Ends

Financial Services

Sector

Shell Companies

Industry

Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

Medera Completes Patient Dosing for Heart Failure Treatment

Medera Completes Patient Dosing for Heart Failure Treatment

Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera, Inc. to Participate in Two Upcoming Investor Conferences

Medera, Inc. to Participate in Two Upcoming Investor Conferences

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera to List on NASDAQ After Merger with Keen Vision Acquisition Corp.

Medera to List on NASDAQ After Merger with Keen Vision Acquisition Corp.

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Trailing total returns as of 3/21/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

KVACU

1.91%

S&P 500 (^GSPC)

4.35%

1-Year Return

KVACU

6.87%

S&P 500 (^GSPC)

7.33%

3-Year Return

KVACU

10.89%

S&P 500 (^GSPC)

26.11%

5-Year Return

KVACU

10.89%

S&P 500 (^GSPC)

144.08%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Keen Vision Acquisition Corporation

11.20

+0.45%

Mkt Cap -

Industry Shell Companies

Charlton Aria Acquisition Corporation

10.30

+1.38%

Mkt Cap -

Industry Shell Companies

Valuation Measures

    Annual 

As of

Market Cap

--
Enterprise Value

--
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

--
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

--
Return on Equity (ttm)

--
Revenue (ttm)

--
Net Income Avi to Common (ttm)

7.41M
Diluted EPS (ttm)

--

Balance Sheet and Cash Flow

Total Cash (mrq)

54.55k
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

--

KVACU does not have Company Insights

KVAC Keen Vision Acquisition Corporation

11.18

-0.04%

LANDP Gladstone Land Corporation

20.09

-0.05%

YHGJ Yunhong Green CTI Ltd.

1.0700

+2.39%

OCCIN OFS Credit Company, Inc.

23.81

+0.17%

TRSNF

1.2350

0.00%

BOWNU Bowen Acquisition Corp

6.40

-9.86%

NETDU Nabors Energy Transition Corp. II

11.50

+2.68%

OCCIO OFS Credit Company, Inc.

24.78

+0.27%

ANG-PB American National Group Inc.

25.05

+0.08%

BSIIU Black Spade Acquisition II Co

10.04

-1.57%

AGM-PG Federal Agricultural Mortgage Corporation

19.57

0.00%

SDPNF SD Guthrie Berhad

1.0000

0.00%

AGM-PE Federal Agricultural Mortgage Corporation

22.70

0.00%

AGM-PF Federal Agricultural Mortgage Corporation

21.00

0.00%

SALRF SalMar ASA

54.04

0.00%

COLZF Coca Cola Icecek Sanayi As

1.5200

0.00%